ghk cu anti cancer effects Frontiers GHK Cu is a copper

If clinically appropriate, your provider recommends a personalized peptide therapy protocol based on your goals

Not for skin and local scalp applications

Summary: GHK-Cu (copper peptide) has shown promise for hair loss in preclinical studies, but no robust human clinical trials have confirmed its efficacy, and it is not recommended by NICE or NHS as an evidence-based treatment

GHK-Cu Monitoring Schedule: Labs & Exams You Need At a glance Drug / GHK-Cu is a tripeptide-copper(II) complex first isolated from human plasma albumin Route / subcutaneous injection or topical (compounded under FDA section 503A) Baseline labs / serum copper, ceruloplasmin, CBC with differential, CMP including liver enzymes Recheck interval / 4 weeks after initiation, then every 8 to 12 weeks Normal serum copper / 70 to 140 g/dL (11 to 22 mol/L) Ceruloplasmin target / 20 to 35 mg/dL Liver enzymes / ALT and AST should remain below 2x upper limit of normal 24-hour urine copper / ordered if serum copper exceeds 155 g/dL on two consecutive draws Skin exam / baseline and every 12 weeks for subcutaneous injection sites Discontinuation trigger / serum copper above 200 g/dL or ceruloplasmin below 15 mg/dL How GHK-Cu Works: Mechanism Before Monitoring GHK-Cu is glycyl-L-histidyl-L-lysine bound to a single copper(II) ion